English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Reduced Immunogenicity of COVID-19 Vaccine in Obese Patients with Type 2 Diabetes: A Cross-Sectional Study

MPS-Authors
/persons/resource/persons224376

Nakayama,  Masanori
Cell Polarity and Organogenesis, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Takahashi, H., Eguchi, J., Watanabe, M., Nakayama, M., & Wada, J. (2024). Reduced Immunogenicity of COVID-19 Vaccine in Obese Patients with Type 2 Diabetes: A Cross-Sectional Study. ACTA MEDICA OKAYAMA, 78(2), 185-191.


Cite as: https://hdl.handle.net/21.11116/0000-000F-5ED3-A
Abstract
The global pandemic of coronavirus infection 2019 (COVID-19) was an
unprecedented public health emerand obesity are critical risk factors
for increased severity of and hospitalization for COVID-19. This is
largely because patients with these underlying medical conditions can
show poor immune responses to the COVID-19 vaccinations. Diabetes is one
of the underlying conditions most highly associated with COVID-19
susceptibility and is considered a predictor of poor prognosis of
COVID-19. We therefore investigated factors that influence the
anti-SARS-CoV-2 spike IgG antibody titer after three doses of
vaccination in patients with type 2 diabetes. We found that obesity was
associated with low anti-SARS-CoV-2 spike IgG antibody titers following
threedose vaccination in type 2 diabetics. Obese patients with type 2
diabetes may have attenuated vaccine efficacy and require additional
vaccination; continuous infection control should be considered in such
patients.